TOP-CABG Trial: Follow-up Extension (TOP-CABG FE)

StatusNot Yet Recruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
To further evaluate the long-term effects of the two antiplatelet strategies on saphenous vein graft patency, long-term adverse cardiovascular events, and bleeding events after coronary artery bypass grafting (CABG), we plan to conduct an extended follow-up study based on the previously completed TOP-CABG trial. This extended follow-up aims to provide high-quality evidence to inform more optimized and individualized long-term antiplatelet management strategies for patients after CABG.
Trial Details
NCT Number NCT07871591
Lead Sponsor China National Center for Cardiovascular Diseases
Conditions
(from sponsor)		 Coronary Artery Disease, Coronary Artery Bypass Grafting, Dual Antiplatelet Therapy, Bleeding, Myocardial Ischemia, Myocardial Infarction
Related terms Coronary Artery Disease, Hemorrhage, Myocardial Infarction, Myocardial Ischemia
Enrollment 2,290 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov